A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the trial is to determine the rate of improvement in objective tumor response, following the addition of ranpirnase to ongoing pemetrexed-carboplatin chemotherapy, for patients with SD or PR following 2 cycles of doublet chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tamir Biotechnology, Inc.
• Treatments: Carboplatin; Pemetrexed; Ranpirnase

Criteria

Inclusion Criteria:

• Age greater than 18 years

• ECOG less than 2

• Estimated survival of greater than 12 weeks

Exclusion Criteria:

• Prior systemic chemotherapy for locally advanced or metastatic NSCLC

• Use of any investigational agent within 28 days prior to registration

• Known hypersensitivity to any of the study drugs

• Brain metastases or leptomeningeal disease

• History of prior malignancy within the past three years